TABLE 1.

Clinical data and muscle sympathetic nerve activity values of heart failure patients (CHF) underwent baroreflex activation therapy procedure and of healthy controls

	BAT–CHF patients, n = 7				Healthy controls, n = 17
Variable	Baseline	6th month	21st month	43rd month	Baseline
BMI (kg/m2)	27.5 ± 2.1	27.2 ± 2.0	27.4 ± 2.1	27.6 ± 2.2	27.0 ± 2.5
Clinic SBP (mmHg)	115.0 ± 5.5	116.4 ± 4.7	110.2 ± 2.9	113.3 ± 2.0	119.4 ± 1.7
Clinic DBP (mmHg)	67.8 ± 2.4	64.3 ± 2.0	65.7 ± 2.0	64.1 ± 2.2	72.5 ± 1.5
Heart rate (bpm)	71.4 ± 2.0	72.0 ± 5.4	68.8 ± 3.9	68.7 ± 4.3	70.6 ± 2.8
6-min walking test (m)	319 ± 19	400.0 ± 37	370.1 ± 48	425.8 ± 39*	n.a.
NYHA class (a.u.)	3 (3–4)	3 (3–4)	2 (2–3)*	2 (2–3)*	0
Minesota score (a.u.)	24.6 ± 5	14.1 ± 3	8.3 ± 2	7.7 ± 2	n.a.
3D LVEF (%)	32.3 ± 2	35.7 ± 3	33.2 ± 3	36.7 ± 3**	56.3 ± 4
3D LVEDV (ml)	159.6 ± 19	142.1 ± 17	134.3 ± 16	137.6 ± 18	109.4 ± 11
EGFR (ml/min/1.73 m2)	79.1 ± 9	86.8 ± 13	81.6 ± 15	88.7 ± 14	84.4 ± 10
No. HF drugs (drugs/day)	4 (3–5)	4 (2–5)	4 (2–5)	4 (2–5)	0
MSNA (bursts/min)	46.2 ± 2.4	30.6 ± 3.2**	31.3 ± 3.0**	26.6 ± 2.0*	24.5 ± 0.8
MSNA (bursts/100 hb)	70.0 ± 4.3	44.1 ± 3.9**	46.0 ± 3.6**	36.9 ± 3.1*	34.1 ± 1.4

In each group, data are shown before (baseline) and at the 6th, 21st and 43rd month after BAT implantation. Data are shown as means ± SEM, except for NYHA class and no. of heart failure (HF) drugs, shown as median values and range. 3D LVEDV, three-dimensional left ventricular end-diastolic volume; a.u., arbitrary units; bpm, beats per minute; CHF, congestive heart failure; EGFR, estimated glomerular filtration rate; hb, heart beats; LVEF, left ventricular ejection fraction; m, meters, MSNA, muscle sympathetic nerve activity; n.a., not assessed; no., number; NYHA, New York Heart Association.

^*P < 0.02 vs. ^**P < 0.05 refer to the baseline vs. statistical significance values, respectively.